AstraZeneca Pharma Share Price Today | Stock Price & AstraZeneca Pharma Share Screener
As of November 19, 2026, the live AstraZeneca Pharma share price (NSE: ASTRAZEN) is ₹6,113.00 on NSE and ₹6,120.45 on BSE, up 1.15% from the previous close, with shares trading between ₹5,994.50 and ₹6,148.50 in today's trading session, and a 52-week range of ₹5,719.50–₹9,226.50. Track AstraZeneca Pharma marketcap in USD to gauge the company's total market size. Use the AstraZeneca Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today AstraZeneca Pharma opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹2,639 and net income of ₹178, with EBITDA of ₹271, an operating margin of 9.0% and a profit margin of 6.7%.
AstraZeneca Pharma Share Price Chart
Track the current stock price of AstraZeneca Pharma with an interactive chart. Analyse ASTRAZEN share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete AstraZeneca Pharma stock quote in one place.
The quote of ₹6,113.00 sits between the 52-week low of ₹5,719.50 and the 52-week high of ₹9,226.50, and the latest session moved 1.15% from the previous close.
AstraZeneca Pharma Company Profile - Fundamental Screener
Screen AstraZeneca Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for ASTRAZEN shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals & Biotechnology industry, with Shilpa Divekar Nirula listed as chairperson or CEO, and it trades under ISIN INE203A01020.
Business Overview
AstraZeneca Pharma India Limited is a biopharmaceutical company incorporated in 1979. It manufactures, distributes, and markets pharmaceutical products, focusing on cardiovascular, renal and metabolism, oncology, and respiratory diseases. The company operates in the healthcare segment and provides clinical trial services to an overseas group company. Key products include Forxiga for...more
Company Details
Classification
Identifiers and Leadership
AstraZeneca Pharma Balance Sheet Screener
Screen ASTRAZEN balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2026, total assets were ₹1,989, up from ₹1,518 in 2025.
Latest statistics put total assets at ₹1,989 and shareholder funds at ₹873, with a leverage ratio of 0.09.
| Item | 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 1,989 | 1,518 | 1,078 | 985 | 857 | 775 | 706 | 562 | 461 | 416 |
| Current Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Fixed Assets | 118 | 64 | 67 | 69 | 75 | 81 | 72 | 75 | 76 | 87 |
Liabilities |
||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 135 | 45 | 9 | 12 | 13 | 15 | 15 | 2 | 7 | 2 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 873 | 770 | 712 | 589 | 511 | 456 | 364 | 301 | 247 | 223 |
| Share Capital | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 |
| Reserves & Surplus | 868 | 765 | 707 | 584 | 506 | 451 | 359 | 296 | 242 | 218 |
AstraZeneca Pharma Income Statement Screener - Profit & Revenue Analysis
Screen AstraZeneca Pharma income statement and profit fundamentals. Analyze ASTRAZEN quarterly results. AstraZeneca Pharma reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For None-None, revenue was ₹2,639 and net profit was ₹178, equal to earnings per unit of ₹71.10, at an operating margin of 9%.
In that period expenses were ₹2,368, interest cost ₹7 and tax ₹54. The next period listed, 2026-March, shows revenue of ₹2,304 and net profit of ₹188.
| Item | None-None | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March | 2015-March |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||
| Revenue | 2,639 | 2,304 | 1,757 | 1,330 | 1,029 | 820 | 826 | 845 | 745 | 583 | 558 | 571 | 523 |
| Expenses | 2,368 | 2,014 | 1,462 | 1,111 | 838 | 719 | 678 | 711 | 657 | 525 | 507 | 547 | 529 |
Operating Costs and Margins | |||||||||||||
| EBITDA | 271 | 291 | 295 | 219 | 191 | 101 | 148 | 134 | 88 | 59 | 51 | 23 | -6 |
| Operating Profit % | 9.00% | 12.00% | 15.00% | 14.00% | 16.00% | 11.00% | 17.00% | 15.00% | 10.00% | 8.00% | 7.00% | 3.00% | -2.00% |
| Depreciation | 20 | 29 | 40 | 15 | 16 | 17 | 20 | 19 | 15 | 15 | 16 | 17 | 15 |
| Interest | 7 | 5 | 2 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Profit and Earnings | |||||||||||||
| Profit Before Tax | 244 | 252 | 156 | 220 | 134 | 83 | 127 | 114 | 73 | 44 | 36 | 6 | -21 |
| Tax | 54 | 65 | 41 | 58 | 35 | 21 | 34 | 42 | 18 | 18 | 15 | 1 | 0 |
| Net Profit | 178 | 188 | 116 | 162 | 99 | 62 | 93 | 72 | 54 | 26 | 20 | 5 | -21 |
| EPS | 71.10 | 75.01 | 46.30 | 64.60 | 39.70 | 24.60 | 37.30 | 28.90 | 21.80 | 10.40 | 8.00 | 2.10 | -8.34 |
AstraZeneca Pharma Cash Flow Screener - Liquidity Fundamentals
Screen ASTRAZEN cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2026-March, operating activities used ₹15, and net cash flow was an outflow of ₹88.
Over the same period, investing activities provided ₹19 and financing activities used ₹92.
| Item | 2026-March | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | -15 | 65 | 28 | 58 | 101 | 105 | 87 | 55 | 9 | 38 |
| Investing Activities | 19 | 31 | 22 | 18 | 5 | 173 | -171 | 4 | -9 | 0 |
Financing and Net Cash | ||||||||||
| Financing Activities | -92 | -66 | -44 | -25 | -10 | -9 | -6 | 0 | 0 | 0 |
| Net Cash Flow | -88 | 31 | 5 | 52 | 96 | 269 | -90 | 59 | -1 | 38 |
AstraZeneca Pharma Shareholding Pattern Screener
See AstraZeneca Pharma shareholding pattern with promoter, FII, and DII holdings. Check AstraZeneca Pharma promoter holding and ownership changes for ASTRAZEN on TickJournal, and see how institutional stock price moves affect the market.
In 2026-Sept, promoters held 75.00%, foreign institutions 2.64%, domestic institutions 7.09% and the public 12.82%, spread across 30,408 shareholders.
The shareholder count was 30,408 in 2026-Sept, compared with 29,338 in 2026-Jun.
| Item | 2026-Sept | 2026-Jun | 2026-Mar | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% | 75.00% |
Institutional Investors | ||||||||
| FII Holding | 2.64% | 2.68% | 2.78% | 2.71% | 2.74% | 3.03% | 2.89% | 2.93% |
| DII Holding | 7.09% | 6.08% | 5.80% | 5.56% | 5.26% | 4.56% | 4.65% | 5.22% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 12.82% | 13.76% | 13.88% | 14.14% | 14.39% | 15.18% | 15.16% | 14.62% |
| Other Holding | 2.45% | 2.48% | 2.55% | 2.59% | 2.61% | 2.23% | 2.31% | 2.24% |
| Shareholder Count | 30,408 | 29,338 | 29,007 | 31,551 | 32,914 | 34,378 | 32,466 | 27,322 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by AstraZeneca Pharma. AstraZeneca Pharma dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹36.00 per unit for 2026-March, a yield of 0.58%, compared with ₹32.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹36.00, ₹32.00 and ₹24.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹36.00 | 0.58% |
| 2025-March | ₹32.00 | 0.41% |
| 2024-March | ₹24.00 | 0.28% |
| 2023-March | ₹16.00 | 0.30% |
| 2022-March | ₹10.00 | 0.31% |
| 2021-March | ₹2.00 | 0.08% |
| 2020-March | ₹1.00 | 0.03% |
| 2019-March | ₹0.00 | 0.00% |
| 2018-March | ₹0.00 | 0.00% |
| 2017-March | ₹0.00 | 0.00% |
AstraZeneca Pharma Stock Index Membership - Nifty & Sensex
See which indices include AstraZeneca Pharma stock. Check ASTRAZEN index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 18 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX BSE500, BSE INDEX MSL400.
Complete Index List
AstraZeneca Pharma Market Events Screener - Corporate Actions
Get AstraZeneca Pharma corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check AstraZeneca Pharma stock events that may affect ASTRAZEN share price, along with derivatives, futures and options activity and sector gainers.
15 corporate actions are listed, the most recent entry being Quarterly Result Announcement dated November 5, 2026, with a record date of November 5, 2026.
It is followed by Quarterly Result Announcement dated August 10, 2026 and Annual General Meeting dated August 10, 2026.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| 2026-11-05 | 2026-11-05 | Quarterly Result Announcement | NA | 1.10% |
| 2026-08-10 | 2026-08-10 | Quarterly Result Announcement | NA | -1.31% |
| 2026-08-10 | 2026-08-10 | Annual General Meeting | NA | 2.06% |
| 2026-07-31 | 2026-07-31 | Dividend | ₹ 36.00 /share | -8.02% |
| 2026-05-26 | 2026-05-26 | Quarterly Result Announcement | NA | 1.20% |
| 2026-02-11 | 2026-02-11 | Quarterly Result Announcement | NA | 4.80% |
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -1.29% |
| 2025-08-14 | 2025-08-14 | Quarterly Result Announcement | NA | -6.00% |
| 2025-08-14 | 2025-08-14 | Annual General Meeting | NA | -4.71% |
| 2025-07-18 | 2025-07-18 | Dividend | ₹ 32.00 /share | 18.54% |
| 2025-05-30 | 2025-05-30 | Quarterly Result Announcement | NA | -0.03% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | 8.88% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | 3.57% |
| 2024-08-08 | 2024-08-08 | Annual General Meeting | NA | 7.26% |
| 2024-07-05 | 2024-07-05 | Dividend | ₹ 24.00 /share | 18.44% |
AstraZeneca Pharma Competitors Screener - Peer Stocks Comparison
Screen ASTRAZEN competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 449,036 | 40.80 | 61,674 | 12.69% | 11,565 | 60.77 |
| Divis Laboratories | 293,316 | 87.70 | 11,067 | 13.95% | 2,568 | 65.94 |
| Torrent Pharmaceuticals | 175,376 | 84.70 | 13,886 | 20.34% | 2,138 | 42.26 |
| Laurus Labs | 125,488 | 94.90 | 6,868 | 22.01% | 890 | 55.82 |
| Zydus Life Science | 119,900 | 27.90 | 27,658 | 17.64% | 5,026 | 55.22 |
| Dr Reddys Laboratories | 116,705 | 42.00 | 35,059 | 3.90% | 4,158 | 73.09 |
| Cipla | 114,474 | 39.20 | 29,045 | 2.24% | 3,870 | 62.07 |
| Mankind Pharma | 108,424 | 47.50 | 14,636 | 14.85% | 1,938 | 62.66 |
| Aurobindo Pharma | 103,355 | 25.90 | 34,145 | 5.56% | 3,503 | 60.69 |
| Lupin | 90,173 | 17.10 | 29,039 | 26.75% | 5,356 | 44.73 |
AstraZeneca Pharma Company Announcements - News & Reports Screener
Screen ASTRAZEN latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated November 19, 2026.
The next most recent announcements are dated November 19, 2026 and November 19, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-11-19 | Revised Submission With Functional Link - Letter Of Intent With Strand Life Sciences Private Limited - Disclosure Of Linkedin Communication | - |
| 2026-11-19 | Letter Of Intent With Strand Life Sciences Private Limited - Disclosure Of Linkedin Communication | - |
| 2026-11-19 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2026-11-07 | Launch Of Datopotamab Deruxtecan (Brand Name: Datverzo) | - |
| 2026-11-05 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Update | - |
| 2026-11-05 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-11-05 | Determination Of Materiality - Details Of Key Managerial Personnel | - |
| 2026-11-05 | Appointment/ Change In Designation Of Senior Management Personnel | - |
| 2026-11-05 | Appointment Of Chief Financial Officer | - |
| 2026-11-05 | Board Meeting Outcome for Outcome Of The Board Meeting Held On Thursday November 5 2026 | - |
| 2026-11-02 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | - |
| 2026-10-30 | Board Meeting Intimation for Meeting Of The Board Of Directors Of The Company To Be Held On Thursday November 5 2026 | - |
| 2026-10-27 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-10-16 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-10-16 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-09-18 | Announcement under Regulation 30 (LODR)-Award_of_Order_Receipt_of_Order | - |
| 2026-09-15 | Closure of Trading Window | - |
| 2026-09-15 | Information Pursuant To Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Resignation Of Senior Management Personnel | - |
| 2026-09-02 | Disclosure Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 - Disclosure Of ESG Rating | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹6,113.00, within a 52-week range of ₹5,719.50 to ₹9,226.50. The P/E ratio is 86.70 and the P/B ratio is 17.54, with earnings per unit of ₹75.01. Market capitalisation stands at ₹15,108.75 Cr and the dividend yield is 0.58%. The company operates in the Healthcare sector, in the Pharmaceuticals & Biotechnology industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on November 20, 2026. This page covers 10 balance sheet periods, 13 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.